RT Journal Article
SR Electronic
T1 Moment-to-moment brain signal variability reliably predicts psychiatric treatment outcome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.17.21251814
DO 10.1101/2021.02.17.21251814
A1 Månsson, Kristoffer N. T.
A1 Waschke, Leonhard
A1 Manzouri, Amirhossain
A1 Furmark, Tomas
A1 Fischer, Håkan
A1 Garrett, Douglas D.
YR 2021
UL http://medrxiv.org/content/early/2021/09/28/2021.02.17.21251814.abstract
AB Biomarkers of psychiatric treatment response remain elusive. Functional magnetic resonance imaging (fMRI) has shown promise, but low reliability has limited the utility of typical fMRI measures as harbingers of treatment success. Strikingly, temporal variability in brain signals has already proven a sensitive and reliable indicator of individual differences, but has not yet been examined in relation to psychiatric treatment outcomes. Here, 45 patients with social anxiety disorder were scanned twice (11 weeks apart) using simple task-based and resting-state fMRI to capture moment-to-moment neural variability. After fMRI test-retest, patients underwent a 9-week cognitive-behavioral therapy. Reliability-based 5-fold cross-validation showed that task-based brain signal variability was the strongest contributor in a treatment outcome prediction model (total rACTUAL,PREDICTED = .77) - outperforming self-reports, resting-state neural variability, and standard mean-based measures of neural activity. Notably, task-based brain signal variability showed excellent test-retest reliability (intraclass correlation coefficient = .80), even with a task length less than 3 minutes long. Rather than a source of undesirable “noise”, moment-to-moment fMRI variability may instead serve as a highly reliable and efficient prognostic indicator of clinical outcome.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02592564Funding StatementWe kindly thank the generous research grants K.M. and T.F. received from the Swedish Research Council (2018-06729, and 2016-02228), and the Swedish Brain Foundation (FO-2016-0106). D.G. and K.M. were supported partially by an Emmy Noether Programme grant from the German Research Foundation to D.G. and by the Max Planck UCL Centre for Computational Psychiatry and Ageing Research in Berlin.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the regional committee at Umea University, Umea, Sweden.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code and statistical software commands will be available online (https://github.com/LNDG/). Due to ethics constraints, we cannot at present make the raw patient data openly available; please contact the first author (K.M.) to discuss potential routes to data access. https://github.com/LNDG/